The survival rate of tumors is often determined by the patient’s own conditions and the type, stage, and progression of the tumor, so we cannot make a generalization about the specific survival time, but in terms of current clinical treatment level and experience, if rectal cancer liver metastases, single metastases or multiple limited metastases, such patients often have a better chance of surgery if their own conditions allow. The postoperative 5-year survival rate is also higher when combined with comprehensive anti-tumor therapy, and the prognosis is often fair.
Patients with poor disease and metastatic conditions, with multiple extensive metastases in the liver and lost to surgery, tend to have a poor prognosis and a lower 5-year survival rate.
At present, rectal cancer is commonly associated with liver metastases and lung metastases. Surgery is the only method that has a chance to cure the tumor. Patients who have the opportunity for surgery are given priority, and those who cannot have surgery can now be treated with a combination of chemotherapy, targeted therapy, immunotherapy, local ablation, and other means. The tumor is a chronic progressive disease process, and maintaining a positive and optimistic attitude both physically and mentally is of great benefit to survival time.